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Abstract: Hendra and Nipah virus, which constitute the genus Henipavirus, are zoonotic 
paramyxoviruses that have been associated with sporadic outbreaks of severe disease and 
mortality in humans since their emergence in the late 1990s. Similar to other 
paramyxoviruses, their ability to evade the host interferon (IFN) response is conferred by 
the P gene. The henipavirus P gene encodes four proteins; the P, V, W and C proteins, 
which have all been described to inhibit the antiviral response. Further studies have revealed 
that these proteins have overlapping but unique properties which enable the virus to block 
multiple signaling pathways in the IFN response. The best characterized of these is the 
JAK-STAT signaling pathway which is targeted by the P, V and W proteins via an 
interaction with the transcription factor STAT1. In addition the V and W proteins can both 
limit virus-induced induction of IFN but they appear to do this via distinct mechanisms that 
rely on unique sequences in their C-terminal domains. The ability to generate recombinant 
Nipah viruses now gives us the opportunity to determine the precise role for each of these 
proteins and address their contribution to pathogenicity. Additionally, the question of 
whether these multiple anti-IFN strategies are all active in the different mammalian hosts for 
henipaviruses, particularly the fruit bat reservoir, warrants further exploration. 
Keywords:  Nipah virus (NiV); Hendra virus (HeV); zoonotic virus; interferon (IFN); 
STAT1; mda-5; nuclear localization 
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1. Overview of the Henipavirus genus 
The Henipavirus genus is part of the paramyxovirus family and consists of two members; Hendra 
virus (HeV) and Nipah virus (NiV) [1]. HeV was first described in 1994 and was associated with an 
outbreak of disease in horses on the East coast of Australia [2]. Humans in contact with infected horses 
were also at risk of infection and two people died during this 1994 outbreak, with another two deaths 
being reported during more recent outbreaks in 2008 and 2009. Nipah virus first emerged in 1998 in 
Malaysia where it was responsible for a large outbreak of disease in pigs as wells as humans that 
worked in the pig industry [3]. In humans, NiV infection causes acute encephalitis and 105 deaths out 
of 265 cases were recorded in this first outbreak. Since then there have been almost yearly reports of 
human infections with NiV from Bangladesh, with mortality rates around 70% and evidence of more 
respiratory disease [4]. HeV and NiV have both been isolated from bats belonging to the Pteropus 
genus (also known as flying foxes) and these animals are considered to be the natural reservoir for 
henipaviruses [5,6]. In Bangladesh there has been no evidence for an intermediate animal host, so 
direct bat-to-human transmission is suspected but there is also increasing evidence for human-to-
human transmission [7]. In addition to bats, humans, horses and pigs, NiV infections of dogs and cats 
have also been reported indicating the wide host range for henipaviruses. This also makes them the 
first examples of zoonotic paramyxoviruses, which together with the high virulence in humans and 
lack of effective therapy, has resulted in them being classified as biosafety level 4 pathogens. 
2. Henipavirus P gene products 
2.1. mRNA editing 
Henipaviruses, as other members of the Paramyxovirinae subfamily, extend the coding capacity of 
their genome via an mRNA editing mechanism that gives rise to multiple proteins from the P gene. 
During transcription of the P gene the polymerase stutters at a run of A and G residues referred to as 
the editing site and this results in the addition of non-templated G residues into the nascent mRNA. An 
unedited henipavirus P mRNA encodes the phosphoprotein (P), which participates in viral RNA 
synthesis as a cofactor for the polymerase. The insertion of one extra G residue shifts the frame and 
this mRNA encodes the V protein (Figure 1). Insertion of two G residues accesses the +2 frame and 
this transcript codes for the W protein. NiV and HeV have been shown to edit their P genes at a 
particularly high frequency, with as many as 14 G insertions observed [8,9]. The overall ratio of 
P:V:W transcripts in NiV-infected cells is approximately 1:1:1 however it has been noted that at early 
times there is a higher proportion of P transcripts and as the infection progresses, the number of V and 
W transcripts exceed that of P [8]. The regulation of this process remains to be investigated and it is 
not yet known whether the same phenomenon can be observed with other paramyxovirus infections. 
Also, due to the high degree of editing, different forms of P, V and W are expected to be produced that 
contain additional glycine residues and it is not known if these lengthened forms have any altered 
function. 
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2.2. Domain structure and localization of the P, V and W proteins 
As a result of the frame-shift that occurs after editing, the P, V and W proteins share the same  
N-terminal domain but have unique C-terminal domains (Figure 1). The common N-terminal domain 
is approximately 100-200 amino acids longer than that of its morbillivirus and rubulavirus 
counterparts, which is one of the distinguishing features of henipaviruses. The extreme N-terminus  
(up to residue 137) of the HeV and NiV P proteins is highly conserved and deletion mapping indicates 
that residues 81-120 in the NiV P protein are crucial for viral polymerase activity [10]. The remaining 
portion of the N-terminal domain shows only 43% identity between NiV and HeV [11]. This may go 
along with the finding that the N-terminal portions of paramyxovirus P proteins are natively unfolded 
and are likely to become structured only when induced to do so upon binding to an interaction partner 
[12]. This allows for incredible flexibility and one can speculate that the increased length of the 
henipavirus P (as well as V and W) proteins may be related to binding of cellular proteins that 
facilitate replication in multiple mammalian hosts. 
The C-terminal domain of the HeV and NiV P protein is conserved and plays an essential role in 
replication as it mediates interaction with the polymerase and the N protein [13]. The C-terminal 
portion of the V proteins of henipaviruses and all other paramyxoviruses is very highly conserved and 
is characterized by the presence of seven cysteine residues. The C-terminus of the henipavirus W 
proteins is another feature unique to these viruses. In the morbilli- and respiroviruses the W ORF ends 
shortly after the editing site, essentially producing a protein representing the N-terminal domain of P. 
In contrast, the henipavirus W ORF extends for 43 amino acids which creates a unique C-terminus. 
Within the C-terminus of the NiV W protein (and conserved in HeV W) lies a basic stretch of amino 
acids that serves as a nuclear localization signal (NLS) (Figure 1) [14]. This has been shown to 
mediate specific interactions with karyopherins 3 and 4 [14], which are related members of the 
nuclear import machinery. The NiV W protein has been shown to be exclusively nuclear both in 
infected cells and when expressed from a plasmid in isolation of other viral proteins [9,14,15]. In 
contrast, the P and V proteins are both found in the cytoplasm [9,15-18]. In infected cells P   
co-localizes with the N protein, consistent with its essential role as part of the viral replication 
complex [9]. The common N-terminal domain of P, V and W has been shown to contain a nuclear 
export signal (NES - residues 174-192) and in the context of the V protein, deletion of this signal 
results in diffuse staining in both the nucleus and cytoplasm [17]. This would indicate that V can 
shuttle between these two compartments but is predominantly cytoplasmic. Presumably the NLS at the 
C-terminus of W overrides the export signal in its N-terminal domain, possibly due to a structural 
conformation that masks the NES. The V and W proteins have also been shown to inhibit NiV   
mini-genome activity which suggests a role in regulating viral RNA synthesis [19]. Along with the P 
protein, both V and W have been detected in preparations of purified NiV particles indicating that they 
can be packaged and therefore delivered to the new target cell upon infection [9]. 
There is limited information on post-translational modifications of P, V and W. As expected, the P 
protein is phosphorylated and specific sites have been identified in HeV P (Ser-224 and Thr-239) and 
NiV P (Ser-240 and Ser-472) [20]. It is not clear whether the sites located in the N-terminal region are 
also phosphorylated in the corresponding V and W proteins and if so how this may affect their 
function. The HeV and NiV V proteins are also described to be phosphorylated by polo-like kinase Viruses 2009, 1                              
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(PLK1), whose binding is dependent on prior phosphorylation of V at a particular site [21]. 
Interestingly, the HeV and NiV V have distinct PLK1 binding sites both of which lie in the N-terminal 
domain. In addition there is now evidence that PLK1 binding and phosphorylation of the parainfluenza 
virus 5 P protein is involved in regulating viral replication, so there is the potential for a similar role 
with henipaviruses, but this still has to be explored [22]. The other modification described for both 
HeV and NiV P proteins is N-terminal acetylation [20]. 
Figure 1. Illustration of the four protein products of the NiV P gene. The P, V and W 
mRNA transcripts are shown in black with the encoded proteins shown below. The   
C protein (encoded by the alternate ORF shown in the P transcript) is depicted in yellow. 
The unique C-termini in V and W, representing the +1 and +2 frames, are shown in green 
and purple, respectively. Functional domains that control protein localization or protein 
interactions are noted. The STAT1 binding domain within the N-terminal portion of P, V 
and W proteins is shown in red. Domains that have been characterized only in the context 
of the V protein are shown in black on the V protein and in gray for the corresponding 
positions on the P and W proteins. NES = nuclear export signal, NLS = nuclear 
localization signal. 
 
 
2.3. The C protein 
The fourth protein encoded by the henipavirus P gene is the C protein, which is expressed from an 
alternate ORF present in P, V and W transcripts. This 18 kDa protein localizes to the cytoplasm in a 
punctate pattern and it can be detected at low levels in NiV virions [9]. Interestingly, a recombinant 
virus that lacks the C ORF shows attenuated growth properties in cell culture, which suggests that 
while not essential for replication, this protein does facilitate virus growth [10]. Possibly this 
attenuation is due to a regulatory defect, as the NiV C protein has been demonstrated to inhibit NiV Viruses 2009, 1                              
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minigenome replication [19]. Other paramyxovirus C proteins that have this property are those from 
measles virus, human parainfluenza virus 3 and Sendai virus.  
3. Inhibition of interferon synthesis by henipavirus V and W proteins 
Cellular detection of virus infection is the trigger for initiating synthesis of IFN-, and the 
molecules described to serve as cytoplasmic sensors for RNA viruses are RIG-I and mda-5 [23,24]. 
The natural ligands for these receptors are viral RNAs and they are characterized by a helicase domain 
and a caspase recruitment domain (CARD). This latter domain mediates an interaction with the 
mitochondrial-bound protein IPS-1 (also known as VISA/MAVS/Cardiff), which triggers a 
downstream signaling cascade to activate the transcription factors IRF3, NF-κB and AP-1 (Figure 2). 
Upon translocation to the nucleus these activated forms bind to the promoter and induce IFN-β 
synthesis. A similar induction of IFN- occurs upon stimulation of some Toll-like receptor (TLR) 
members [24] and both TLR and RIG-I-like signaling pathways are targeted by viruses as a means to 
suppress activation of the host antiviral response [25]. 
Figure 2. Illustration of virus-activation of IFN-β synthesis and its inhibition by the 
henipavirus V and W proteins. Detection of viral RNAs by RIG-I and mda-5 activates a 
signaling cascade though IPS-1 leading to the phosphorylation of IRF3 and NFκB. The 
activated transcription factors translocate to the nucleus and induce synthesis of IFN-β. 
The V protein prevents signaling by interacting with mda-5, while the W protein interferes 
with the activated form of IRF3 in the nucleus. 
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3.1. Interaction of the V protein with RNA helicases, mda-5 and LGP2 
Paramyxovirus V proteins limit the synthesis of type I IFN via a highly conserved mechanism [26]. 
A study using a recombinant PIV5 provided a clue that this function could be attributed to the   
C-terminal domain of V, as a virus lacking this domain induced greater levels of IFN- than the wild-
type PIV5 [27]. Reporter assays have shown that the block is at the level of transcriptional activation, 
as the V proteins of a number of paramyxoviruses, including NiV [14], can prevent activation of the 
IFN- promoter in response to cytoplasmic dsRNA [26]. This is also true of other IRF3-dependent 
promoters (e.g., ISG54, ISG56), indicating that the signaling pathway leading to IRF3-activation is 
being targeted [14]. For NiV, it has been shown that V is unable to prevent IRF3 activation in response 
to TLR3-mediated signaling, which suggested that it is acting specifically on the virus- or intracellular 
dsRNA-trigged pathway for IFN induction. The first description of the RNA helicase, mda-5, and its 
signaling role in the IFN induction pathway provided an explanation for these early findings [28]. It 
was found that the V proteins can interact with mda-5 via their cysteine-rich   
C-terminal domains and thereby prevent downstream signaling and hence, activation of the IFN- 
promoter (Figure 2) [28,29]. V acts by binding to the helicase domain of mda-5 through a minimal 
region encompassing residues 701-816 [30,31]. In one study this interaction was shown to prevent 
binding of dsRNA and subsequent oligomerization of mda-5 [30], while another indicated that ATP 
hydrolysis is inhibited [31]. The paramyxovirus V proteins can also bind to an analogous domain in 
the helicase portion of LGP2 [31]. LGP2 lacks the N-terminal CARD domain and therefore is not an 
active signaling molecule but is thought to play a role in the regulation of IFN induction by RIG-I and 
mda-5 [23]. The role of the V:LGP2 interaction in the IFN response remains to be determined. 
The V proteins are notably unable to interact with or inhibit signaling from the related RNA 
helicase, RIG-I [29]. Due to the more pronounced effect of RIG-I deficiency on virus induction of IFN, 
RIG-I is thought to be the predominant sensor for most viral infections. Thus it is unclear whether the 
lack of V-mediated inhibition implies that RIG-I is not involved in sensing paramyxovirus infections 
or whether paramyxoviruses can target RIG-I via additional proteins. That said, there are reports of 
mda-5 being important for the detection of Sendai virus defective interfering particles in dendritic cells 
[32], so assessing the true biological role of mda-5-inhibition may be a limitation of the tools at hand. 
3.2. W-mediated inhibition of IFN production from the nucleus 
Like the V protein, the W protein of NiV can also prevent activation of the IFN- promoter that is 
triggered by virus or intracellular dsRNA [14]. As W has a completely different C-terminal domain 
from V, it does not contain the mda-5 interaction motif, so it must act via an alternative mechanism. 
NiV W also has the ability to interfere with TLR3 signaling, which V is unable to do [14]. These data 
indicate that the W protein can target IFN synthesis via a unique mechanism. The other unique feature 
of W is its nuclear localization and it was shown that a mutant W protein that lacks its NLS loses the 
ability to block TLR3 signaling [14]. Correspondingly, if the V protein is artificially targeted to the 
nucleus, it gains the ability to inhibit TLR3-mediated signaling. These data show firstly, that nuclear 
localization is critical for this activity and secondly, that the domain responsible for mediating the 
inhibition must lie within the common N-terminal domain shared by V and W. The TLR3 and virus-
activated signaling cascades that lead to induction of IFN- involve unique signaling molecules but at Viruses 2009, 1                              
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some point they converge and activate the same set of transcription factors required for activating  
IFN- gene expression. Therefore if W is acting in the nucleus it is conceivable that it is interfering 
with a final step in the pathway that is required for signaling events derived from multiple sensors. 
IRF3 is known to be a critical component and the presence of phosphorylated forms in the nucleus is 
used as a signature for an active IFN response. In the presence of NiV W IRF3 is phosphoylated in 
response to TLR3 signaling, however as the amount of W is increased there is an accompanying loss 
of the activated form of IRF3, which is not seen with the V protein [14]. This implies that W does not 
block activation of IRF3 but that once this active form is in the nucleus it is less stable in the presence 
of NiV W which prevents proper activation of the IFN- promoter (Figure 2). Clearly, the precise 
mechanism by which NiW acts remains to be determined but it would appear that the presence of an 
NLS in its unique C-terminus, and hence an altered distribution compared to V, confers on this protein 
an additional means by which to inhibit the IFN response. As NiV and HeV are distinct in having  
W proteins with extended C-termini, this may indicate that this additional anti-IFN mechanism is 
unique to the henipavirus genus. 
4. Inhibition of interferon signaling by henipavirus P, V and W proteins 
Both type I (/) and type II () interferons (IFN) mediate their effects on cells by binding to 
receptors on the cell surface and activating the JAK-STAT signaling pathway [33]. STAT (Signal 
Transducers and Activators of Transcription) proteins are transcription factors that are mainly 
cytoplasmic in their inactive state. In response to IFN-/, STAT1 and STAT2 become tyrosine 
phosphorylated, dimerize, and translocate to the nucleus (Figure 3). The activated heterodimer 
complexes with interferon regulatory factor (IRF) 9 to form the ISGF3 (IFN stimulated gene factor 3) 
complex. ISGF3 binds to IFN-stimulated response elements (ISRE) located in the promoters of   
IFN-stimulated genes (ISG) and activates transcription leading to the production of many proteins that 
have antiviral activity. For this reason many viruses have mechanisms to inhibit the JAK-STAT 
signaling pathway and paramyxoviruses in particular have a preference for targeting the STAT 
proteins [34]. Interestingly, they do so via distinct mechanisms and the henipaviruses act by 
sequestering STATs and preventing their activation in response to IFN.  
4.1. STAT re-localization and inhibition of IFN-activated phosphorylation 
In the presence of either NiV P, V or W proteins, there are reduced levels of tyrosine 701 
phosphorylated STAT1 in IFN-/-treated cells [15,18]. This lack of STAT1 phosphorylation 
corresponds with an inhibition of ISRE-driven gene expression in cells that are expressing these 
proteins, indicating that the IFN signaling pathway is not being activated [15,18,35]. STAT1 is also 
required for IFN--mediated signaling and this pathway is also blocked by expression of both HeV and 
NiV V proteins [16,18], and presumably also the P and W proteins. The finding that P, V and W share 
this activity suggests that the domain responsible lies within the common N-terminal region and 
indeed, when this domain is expressed alone it too shows the ability to block IFN signaling [15,35]. On 
an individual basis though, it has been shown that at limiting concentrations, P has the weakest activity 
and W the strongest, suggesting that the properties of the full-length proteins can modulate this activity 
[15]. Viruses 2009, 1                              
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Figure 3. Illustration of the type I IFN signaling pathway and its inhibition by the 
henipavirus P, V and W proteins. IFN-α/β binds to the IFN-α/β receptor (composed of 
IFNAR1 and IFNAR2 subunits). The receptor-ligand interaction activates the Janus 
protein tyrosine kinases, TYK2 and JAK1, which in turn activate the STAT1 and STAT2 
transcription factors via tyrosine phosphorylation. The phosphorylated STATs form a 
heterodimer and translocate to the nucleus where together with IRF9, they form the ISGF3 
(IFN stimulated gene factor 3) complex. This transcription factor complex binds to IFN-
stimulated response elements (ISRE) and activates transcription of IFN-stimulated genes 
(ISG). The P and V proteins bind to STAT1 (and STAT2 for V) in the cytoplasm and 
prevent its activation in response to IFN. The W protein acts via the same mechanism but it 
sequesters STAT1 in the nucleus in an inactive form. 
 
 
In an unstimulated cell STAT1 shuttles between the cytoplasm and nucleus but upon IFN treatment, 
the phosphorylated and dimerized form translocates to the nucleus. In cells that are expressing P and V 
proteins, STAT1 is retained exclusively in the cytoplasm in its inactive, non-phosphorylated form even 
in the presence of IFN-/ or IFN- [15,16,18]. The V proteins of both NiV and HeV have also been 
shown to sequester STAT2 in the cytoplasm and prevent its nuclear accumulation in response to   
IFN-/ [16,18]. However, in cells expressing the W protein, the inactive form of STAT1 is   
re-localized to the nucleus [15]. The status of STAT1 in NiV-infected cells has recently been examined 
and there is no evidence of phosphorylated STAT1, which correlates with the plasmid-expression data 
and indicates that IFN signaling is not active in infected cells [10]. Interestingly the inactive form of 
STAT1 is completely localized to the nucleus in the infected cells but remains cytoplasmic in non-Viruses 2009, 1                              
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infected cells [10]. This mimics the pattern seen in W-expressing cells and suggests that the NiV W 
protein is most likely mediating this effect in infected cells. 
4.2. Interaction with STAT1 and STAT2 
As suggested by the strong co-localization data, the P, V and W proteins can all interact with 
STAT1 [10,15-18]. The V protein has also been shown to interact with STAT2 and in the presence of 
V, both STAT1 and STAT2 are found in high-molecular weight complexes, which indicates that they 
are sequestered into a large, multi-protein complex [16,18].  
The STAT1 binding domain lies within the N-terminal portion of P, V and W [10,15,17]. Finer 
mapping has shown that a 30 amino acid region spanning residues 111-140 of P/V/W is critical for the 
interaction (Figure 4) and that loss of binding correlates with an inability to prevent STAT1 
phosphorylation and to inhibit IFN signaling [10]. A glycine at position 125 within this binding 
domain has been implicated in IFN signaling inhibition as the V protein from a human isolate of NiV 
which contains a glutamic acid at this position was shown not to bind to STAT1 or STAT2 [36]. 
Ciancanelli et al. [10] examined the contribution of surrounding glycine residues within the binding 
domain and in addition to confirming the importance of G125, they reported that substitution of 
glutamic acid for glycines at positions 121, 127 and 135 (but not 120) could all abrogate STAT1 
binding in the context of P, V and W proteins. This correlated with the ability to prevent IFN 
signaling, although the G135E mutant retained more activity than the other mutants despite not visibly 
interacting with STAT1. The contribution of tyrosine 116 within the defined STAT1 binding domain 
was also examined due to the known requirement of a tyrosine within a similar motif in the measles 
virus P protein for STAT1 inhibition [37]. Mutation of tyrosine 116 in NiV P to either alanine or 
glutamic acid resulted in loss of IFN inhibitory activity and loss of STAT1 binding [10]. Interestingly, 
a P protein with a Y116F substitution retains the ability to block IFN signaling and to bind STAT1, 
indicating the requirement for an aromatic residue at this position. Another study addressed the 
contribution of residues that make up an SSP motif in the N-terminal domain of P, V and W. These 
residues lie within the STAT1-binding domain and, in the context of the NiV V protein, have been 
shown to mediate an interaction with PLK1 [21]. For both NiV and HeV V proteins, alanine 
substitution of the serine residues at positions 130 and 131 resulted in loss of STAT1 and STAT2 
binding activity and a corresponding loss of ability to inhibit both IFN-/ and IFN- signaling. For 
position 130, substitution with threonine did not disrupt STAT binding despite the fact that this 
mutation does eliminate the interaction of NiV V with PLK1. These and other supporting data led to 
the conclusion that V-mediated interactions with STAT proteins and PLK1 are separable functions 
[21]. 
In order to verify the importance of the residues conferring STAT1-binding within the context of 
the whole virus, it was necessary to determine whether they were also required for the polymerase  
co-factor function of the P protein. Using a NiV mini-genome assay to assess polymerase function, it 
was shown that the critical region for RNA synthesis lies within amino acids 81-113 of the P protein 
and that substitutions that affect STAT1 binding do not interfere with polymerase activity [10,21]. This 
information allowed the construction of a recombinant NiV that lacked STAT1 binding activity due to 
a G121E mutation in the P, V and W proteins [10]. As this region overlaps with the C ORF and would Viruses 2009, 1                              
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result in an amino acid change in C, this virus was engineered in a C knockout background. NiV C
KO 
and C
KO/G121E viruses display identical growth properties in both 293T and Vero cells, although 
interestingly both are attenuated relative to the wild-type NiV. Crucially, infection with the 
C
KO/G121E virus induces STAT1 phosphorylation in response to IFN- whereas WT and C
KO viruses 
do not [10]. Also, normal nuclear translocation patterns for STAT1 are observed in NiV C
KO/G121E 
infected cells in response to IFN. In contrast the inactive form of STAT1 remains sequestered in the 
nuclei of NiV WT and C
KO infected cells. As mentioned earlier, these data suggest that the nuclear W 
protein is functioning as the main obstacle to IFN signaling and that this is abolished by the G121E 
mutation, which eliminates the STAT1 interaction. The finding that the recombinant NiV lacking 
STAT1-binding has identical growth properties to its C
KO parent virus, even in 293T cells (which have 
a functional IFN response), indicates that the lack of STAT1 inhibition is not detrimental to the virus. 
This suggests that additional anti-IFN mechanisms encoded by NiV are probably still intact. These 
could be either V-mediated inhibition of mda-5, W-mediated inhibition of IRF3 activity in the nucleus, 
or both acting in concert. 
Figure 4. An alignment of the STAT1 binding domain (residues 111-140) in the P, V and 
W proteins of NiV and HeV. Those residues that have been shown to be critical for the 
STAT1 interaction are shown in red. 
 
 
To date, only the V protein has been reported to interact with STAT2 [16,18,36]. This interaction is 
dependent on STAT1 as it has been shown that in STAT1 negative cells, there is no V:STAT2 
interaction and so far all mutations in V that eliminate STAT1 binding have resulted in a simultaneous 
loss of STAT2 binding [17,21,36]. However, Rodriguez et al. [17] also demonstrated that a NiV V 
protein lacking residues 230-237 was deficient in STAT2-binding despite being able to interact with 
STAT1. This led them to the conclusion that for STAT2 to interact with V, both the STAT1 binding 
site and this STAT2-specific site are required. The precise role for the STAT2 interaction remains 
unclear, as the ability to prevent IFN signaling appears to be strictly dependent on STAT1 binding and 
inhibition. 
Currently, there is limited information regarding the region of STAT1 that interacts with the NiV 
proteins. The domain structure of STAT1 can be broadly divided into an N-terminal domain, a coiled-
coiled region, a DNA-binding domain, a linker domain, an SH2 domain and a transactivation domain 
[38]. Using a set of STAT1 and STAT3 (which does not interact with V) chimeric constructs, it has 
been possible to map the NiV V-interaction site to amino acids 509-712 on STAT1 [17]. This 
incorporates the linker domain and the SH2 domain as well as tyrosine 701 which is the residue 
phosphorylated in response to IFN. Viruses 2009, 1                              
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5. The unexplored role of the C protein 
Of all the henipavirus P gene products, we know the least about the C protein. Plasmid-based 
expression of the NiV C protein has been shown to prevent the induction of a robust antiviral response 
[35] but the mechanism by which it acts is unknown. Perhaps the strongest indication for the 
importance of the C protein is shown by the recombinant NiV C
KO virus which has attenuated growth 
properties relative to the wild-type virus [10]. The fact that this is seen in Vero cells as well suggests 
that this phenotype is not mediated by IFN and it may reflect the role of the C protein in regulating 
viral RNA synthesis [19]. 
6. Conclusions 
In conclusion, through their unique coding strategy, henipaviruses produce multiple proteins that 
antagonize the antiviral response at multiple levels. While the shared N-terminal domains of the P, V 
and W proteins direct inhibition of STAT signaling, the C-terminal domains of the V and W proteins 
confer unique properties on these proteins that extend their antagonist function. For V this involves 
mda-5-binding and for W this involves nuclear localization and the ability to block a late stage of the 
IFN induction pathway. The question of whether all these mechanisms are active in an infected cell is 
something that still needs to be explored. Unfortunately the need for biosafety level 4 conditions has 
limited this work but the description of a reverse genetics system for NiV opens the door to addressing 
the contribution of each protein and/or mechanism. Another factor to consider is that the presence of 
multiple anti-IFN mechanisms may relate to the zoonotic nature of these viruses. Even though it has 
already been shown that the NiV V protein can prevent IFN signaling in cells from multiple species 
[36], some of the other viral proteins may have species-specific activity. It is of particular interest to 
explore this possibility in pteropid bats, which are the natural reservoir of henipaviruses and from all 
accounts seem to control virus infection far better than other mammalian hosts [39]. 
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